FDA clears Masimo wearable monitor to detect opioid-related breathing risk

Masimo, a Danaher company specializing in patient monitoring technology, announced Monday that it has received FDA 510(k) clearance for a new feature that detects opioid-induced respiratory depression (OIRD) using its Radius VSM wearable continuous patient monitor.

The capability is powered by Masimo's next-generation smartSET pulse oximetry sensor platform, which applies pattern recognition to continuous physiologic data to help clinicians spot early signs of respiratory compromise in hospital patients receiving opioid therapy. The clearance marks the first time Masimo's OIRD detection technology has been built into a hospital monitoring system.

The new feature pairs Masimo's SET pulse oximetry signal processing with AI-enabled analysis, a combination the company says shifts pulse oximetry's role from simply tracking vital signs to surfacing actionable clinical insight. Rather than relying on a single measurement, smartSET evaluates relationships across multiple physiological parameters, building on the company's existing RD SET sensor technology.

"Opioid-Induced Respiratory Depression remains a critical patient-safety concern," said Dr. Basil Matta, chief medical officer at Masimo, in a statement. He said the OIRD detection feature is designed to help clinicians identify changes in respiratory status earlier than traditional monitoring methods typically allow, and reflects the company's effort to work with clinicians on patient-safety challenges.

Radius VSM is a wearable, tetherless, modular monitor designed for continuous tracking of patient status throughout a hospital stay, with the ability to customize which parameters are monitored for each patient. With the addition of smartSET and OIRD detection, the platform now includes visual alarms that notify clinicians of changes in a patient's condition and escalate as OIRD risk increases. Those alerts appear on the device itself and can also be routed to remote or centralized monitoring stations.

Masimo said it is developing additional pattern-recognition algorithms for the smartSET platform, with plans to extend the technology into other hospital monitoring products as part of its broader connected care ecosystem.

Sector trends: AI and wearable monitoring

The clearance arrives amid a broader push across the patient-monitoring industry to combine wearable sensors with artificial intelligence to catch clinical deterioration before it becomes an emergency. Hospitals have increasingly sought tools that move beyond static vital-sign snapshots toward continuous, ambient monitoring that can flag subtle trends a busy clinical staff might otherwise miss.

Respiratory depression tied to opioid administration has been a persistent focus of patient-safety initiatives, given that postoperative and inpatient opioid use carries a risk of complications that can escalate quickly if undetected. Regulatory and accreditation bodies have for years urged hospitals to adopt continuous monitoring for at-risk patients rather than relying solely on intermittent spot checks by nursing staff.

More broadly, AI-enabled pattern recognition is becoming a common thread in next-generation medical devices, as manufacturers look to extract more clinical value from existing sensor data rather than simply adding new hardware. Industry analysts have pointed to this kind of software-driven enhancement — layering predictive or early-warning algorithms onto established sensor platforms — as a cost-effective way for health systems to improve safety outcomes without large capital investments in new equipment. Wearable, tetherless monitoring formats have also gained traction as hospitals try to extend surveillance to lower-acuity units and general care floors, where continuous monitoring was historically less common than in intensive care settings.